Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,299 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06077591Recruiting
Genetic and organoid testing to guide cancer treatment
This trial uses advanced testing (genetic sequencing and lab-grown tumor models) to find the best treatment for people with advanced solid tumors that haven't responded to at least one standard treatment. The goal is to personalize therapy based on your tumor's unique features.
Hong Kong, N.T.Ages 18–100 - NCT06047977RecruitingPhase 1
Immune cell therapy for high-risk solid tumors in children and young adults
This trial uses a patient's own tumor-fighting immune cells (TILs) to treat high-risk solid tumors outside the brain in children and young adults. It has two parts: first, a tumor sample is collected during surgery, and then the immune cells are grown in a lab and given back to the patient to attack the cancer.
St. Petersburg, FloridaAges 1–21 - NCT05691517RecruitingPhase 1
Test drug CBX-12 in advanced cancers and monitor your response
This Phase 1 study tests how your body handles the drug CBX-12 in people with advanced solid cancers that have already tried prior treatments. It may help researchers learn safe dosing and how tumors respond, and you may be asked to provide biopsy samples.
Bethesda, MarylandAges 18 years+ - NCT05663502Recruiting
Donate blood and tissue samples for HIV-related cancer research
This study collects blood and tissue samples to help researchers learn more about cancers related to HIV/AIDS. You may be able to join if you’re 18+ and have HIV and a cancer diagnosis, or (if HIV-negative) a certain cancer that is closely linked to AIDS-related cancers.
La Jolla, CaliforniaAges 18 years+ - NCT05222620RecruitingPhase 2
SRS methods for untreated brain metastases under 4 cm
This trial compares two stereotactic radiation strategies for patients who have intact (not previously radiated) brain metastases that are limited in size. It aims to see which approach works best in controlling the cancer while reducing side effects.
Scottsdale, ArizonaAges 18 years+ - NCT05124912Recruiting
Laser treatment for recurrent brain metastases after prior SRS
This study tests whether repeating treatment with a laser (along with a small biopsy) can control brain metastases that have come back after earlier radiation called SRS. It may help people whose cancer is stable enough for surgery and who have a specific, reachable brain spot to target.
Los Angeles, CaliforniaAges 18 years+ - NCT04511039RecruitingPhase 1
New targeted pill combo for advanced colon or stomach cancers
This Phase 1 trial tests a combination of oral (swallowed) drugs—trifluridine/tipiracil plus talazoparib—in people with advanced (locally advanced or metastatic) colorectal or gastroesophageal adenocarcinoma. It’s designed to see how well the treatment can control cancer and to better understand side effects and dosing.
Buffalo, New YorkAges 18 years+ - NCT04308330RecruitingPhase 1
Vorinostat plus chemotherapy for advanced tumors in brain
This Phase 1 trial studies how safe and tolerable vorinostat is when combined with chemotherapy for cancers that have come back or are hard to treat, including tumors in the brain or spinal cord. It may help doctors find a better way to treat advanced solid tumors and CNS (brain/spinal cord) cancers.
Valhalla, New YorkAges 1–30 - NCT04055649RecruitingPhase 2
Test of ONC201 and weekly paclitaxel for platinum-resistant ovarian cancer
This Phase 2 study tests whether ONC201 given with weekly paclitaxel can control platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It may help by shrinking tumors or slowing growth in people whose cancer has progressed after platinum chemotherapy.
Detroit, MichiganAges 18 years+ - NCT03604315RecruitingPhase 1
PET/CT scan testing a new radioactive tracer for tumors
This early-phase study uses PET/CT scans to see how well a new radioactive tracer (a tiny dose of a special material) highlights solid tumors in the body. It may help researchers learn whether this tracer can better find and track tumor spots seen on standard scans.
Houston, TexasAges 18 years+ - NCT05528055RecruitingPhase 1
Safety study of SCR-6920 for advanced cancers
This Phase 1 trial tests whether SCR-6920 capsules are safe and tolerable in people with advanced, treatment-resistant cancers. It may help doctors learn the right way to dose the medicine and check for side effects.
Jinan, ShandongAges 18–75 - NCT05501353Recruiting
Study tumor biomarkers in recurrent metastatic colon cancer
This study looks for blood/tumor signals (“biomarkers”) that may help predict outcomes in people whose colorectal cancer returns and spreads after surgery. It mainly helps researchers understand who may do better or worse, which can guide future care.
Hangzhou, ZhejiangAges 18–99 - NCT05444478Recruiting
Microwave ablation plus lenvatinib for recurrent liver cancer
This trial tests whether combining heat treatment to kill liver tumors (microwave ablation) with the medicine lenvatinib can better control recurrent hepatocellular carcinoma (HCC). It may help shrink tumors or slow growth for people whose cancer has come back but who have limited tumor burden.
Changsha, HunanAges 18–75 - NCT04902937Recruiting
Testing how added radiation may work by immune and tumor markers
This study looks at people with non-metastatic invasive breast cancer who are getting curative breast surgery followed by planned radiation (sometimes with other anti-cancer medicines). Researchers want to understand whether a patient’s age and certain immune/tumor blood features can predict how well radiation helps.
JenaAges 18 years+ - NCT05189054Recruiting
Radiation retreatment for very central chest tumors
This trial tests a focused form of radiation (SBRT) to treat tumors in the very center of the chest that have already been treated with radiation before. It aims to check safety and whether the tumor can be controlled without causing unacceptable side effects.
Beijing, Beijing MunicipalityAges 18–80 - NCT05969041RecruitingPhase 1
Early-phase drug trial for advanced epithelial cancers
This Phase 1 study tests a new drug (MT-302) in adults with advanced or metastatic epithelial cancers that have worsened or stopped responding to standard treatment. The goal is to see how the drug works and whether it is safe for people with limited options.
Darlinghurst, New South WalesAges 18 years+ - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Scottsdale, ArizonaAges 18 years+ - NCT06305910RecruitingPhase 1
Vaccine immunotherapy for recurrent brain tumors or newly diagnosed DIPG
This trial tests a combination of a vaccine made from tumor cells and a drug that may boost the immune system's ability to fight brain tumors. It is for children and young adults with a recurrent high-grade glioma or a newly diagnosed diffuse midline glioma with a specific genetic marker (H3K27M).
Minneapolis, MinnesotaAges 2–25 - NCT06301945Recruiting
AI tool for thymus tumors
This study is using an artificial intelligence tool to help doctors better predict how thymus tumors (thymoma and thymic carcinoma) will behave. It may help guide decisions about treatment and follow-up.
Rotterdam, South HollandAges Any age - NCT06410092RecruitingPhase 1
Safety study of FTL001 for advanced solid tumors
This trial tests a new drug called FTL001 for people with advanced solid tumors that have not improved with standard therapy. The goal is to see if it is safe and how well it works.
Beijing, Beijing MunicipalityAges 18–75 - NCT05352178RecruitingPhase 3
Targeted treatment for few-spread prostate cancer spots
This Phase 3 trial tests whether treating only a small number of prostate cancer metastases can help people with “oligorecurrent” (limited repeat) prostate cancer. It may reduce cancer activity while avoiding broader whole-body treatment for some patients.
LeuvenAges 18 years+ - NCT07755826Recruiting
Repotrectinib safety study in Japanese children with NTRK fusion tumors
This study tracks the safety and effects of the drug repotrectinib in children aged 4 to under 18 with certain tumors that have a specific genetic change (NTRK fusion). The goal is to see how well the drug works in everyday medical practice in Japan.
Minato-ku, TokyoAges 4–17 - NCT07744074Recruiting
Carbon-ion radiation for large chest tumors
This trial tests a new type of radiation using carbon ions to treat large tumors in the chest that have come back or not responded to prior treatments. It aims to see if this therapy is safe and effective for people who have few options.
Hangzhou, ZhejiangAges 18 years+ - NCT07718243RecruitingPhase 1/Phase 2
Combining two immunotherapies for solid tumors, melanoma, and lung cancer
This trial tests a new drug (bexmarilimab) plus nivolumab (an approved immunotherapy) for people with advanced solid tumors, melanoma, or non-small cell lung cancer (NSCLC) that has stopped responding to standard treatments.
ManchesterAges 18 years+
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,299 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.